| scholarly article | Q13442814 |
| P356 | DOI | 10.1310/EWWC-YLJ6-8LHE-054A |
| P8608 | Fatcat ID | release_m7uzeazywfdqhd3hka3feej2l4 |
| P698 | PubMed publication ID | 16452064 |
| P2093 | author name string | Leonardo Calza | |
| Roberto Manfredi | |||
| Francesco Chiodo | |||
| P2860 | cites work | An extremely different dysmetabolic profile between the two available nonnucleoside reverse transcriptase inhibitors: efavirenz and nevirapine | Q45239039 |
| Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998. | Q45965936 | ||
| First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients | Q46248542 | ||
| Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. | Q50145200 | ||
| Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study | Q34546335 | ||
| Interactions between recreational drugs and antiretroviral agents | Q34874414 | ||
| HIV disease and advanced age: an increasing therapeutic challenge | Q34967154 | ||
| Non-nucleoside reverse transcriptase inhibitors--an overview | Q35093731 | ||
| Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management | Q35685244 | ||
| Nevirapine in the treatment of HIV. | Q35917412 | ||
| The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals | Q42627921 | ||
| Gabexate mesilate and/or octreotide in human immunodeficiency virus-associated pancreatic abnormalities | Q42683244 | ||
| Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients | Q43461248 | ||
| Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections | Q43851688 | ||
| A prospective comparison of the two main indications of efavirenz in 2001 highly active antiretroviral therapy (HAART) regimens: first-line versus salvage use. | Q43988702 | ||
| Normalization of liver enzymes in an HIV-hepatitis C virus-co-infected patient after potent antiretroviral therapy | Q43988881 | ||
| Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy | Q44044990 | ||
| Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals | Q44131292 | ||
| Mortality due to chronic viral liver disease among patients infected with human immunodeficiency virus. | Q44169170 | ||
| Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients | Q44399527 | ||
| Incidence of liver toxicity in hiv-infected patients receiving isolated dual nucleoside analogue antitretroviral therapy | Q44517773 | ||
| Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients | Q44660478 | ||
| Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals | Q44727378 | ||
| Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study | Q44849439 | ||
| No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors | Q44905262 | ||
| The relationship between nevirapine plasma concentrations and abnormal liver function tests | Q45016090 | ||
| P433 | issue | 6 | |
| P921 | main subject | efavirenz | Q422645 |
| P304 | page(s) | 302-311 | |
| P577 | publication date | 2005-11-01 | |
| P1433 | published in | HIV Clinical Trials | Q15756361 |
| P1476 | title | Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine | |
| P478 | volume | 6 |
| Q39530519 | Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients |
| Q57180639 | Drug-drug interactions and clinical considerations with co-administration of antiretrovirals and psychotropic drugs |
| Q37139458 | EFV/FTC/TDF-associated hepatotoxicity: a case report and review |
| Q41392118 | Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy |
| Q30240127 | Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals |
| Q24235724 | Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals |
| Q36787311 | Efavirenz: a review |
| Q33795242 | Expenditures for the care of HIV-infected patients in rural areas in China's antiretroviral therapy programs. |
| Q36984240 | Idiosyncratic drug-induced liver injury: an overview |
| Q48254303 | Pooled week 96 results of the phase III DUET-1 and DUET-2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interest |
Search more.